Psychedelic-assisted therapy for
cancer, PTSD, depression, and trauma.
Advancing Psychedelic Therapy Through Clinical Research
Expertise Informed by Experience
Sunstone is guided by a team of Clinical Research Coordinators with over 30 years of combined clinical expertise and over 5 years of specialized experience in psychedelic research.
We are currently offering trials to address depression, treatment-resistant depression, postpartum depression, cancer and depression, adjustment disorder, and PTSD. These trials use a variety of psychedelic compounds including, but not limited to psilocybin, MDMA, and 5-MeO-DMT.
Explore Open Studies- Adjustment Disorder (AD)
- Advanced Illness
- Generalized Anxiety Disorder
- Major Depressive Disorder (MDD)
- MDD and Cancer
- Post-Traumatic Stress Disorder
- Postpartum Depression
- Treatment-Resistant Depression
- Psilocybin
- MDMA
- LSD
- 5-MeO-DMT
- Methylone
- RE-104 (novel serotonergic antidepressant)
- atai Life Sciences
- Beckley Psytech
- Compass Pathways
- Cybin
- Lykos Therapeutics
- Reunion Neuroscience
- Transcend Therapeutics
- Usona Institute
- Adventist HealthCare
- Dana-Farber Cancer Institute
- Johns Hopkins Center for Psychedelic &
Consciousness Research - McGill University
- Memorial Sloan Kettering Cancer Center
- The University of Vermont
Participating in a clinical trial at Sunstone contributes to advancing scientific knowledge in the field of mental health research. Sunstone’s clinical team has authored 11 papers on psychedelic research in leading journals, including Cancer, JAMA Oncology, and NIH-Heals.
View Published Research
Our Mission
Sunstone in the News
Co-founder and CEO, Dr. Manish Agrawal, recently shared his expertise and vision for the future of psychedelic-assisted therapy in oncology in a four-part interview series with Pharmacy Times’ Lead Editor, Alana Hippensteele.
Sunstone is pleased to begin enrollment of two clinical studies exploring the therapeutic potential of DMT (N,N-dimethyltryptamine) and its analogs.
June 16, 2025 | A new study conducted by Sunstone Therapies suggests that a single dose of psilocybin, combined with psychological support, can provide sustained relief from depression for some cancer patients.
Manish Agrawal, MD, Co-Founder and CEO of Sunstone Therapies Manish Agrawal, MD, brings an extensive academic, clinical, and research background […]
Kimberly Roddy, MBA, Co-Founder and COO of Sunstone Therapies Kimberly Roddy is the Co-Founder and Chief Operations Officer of Sunstone […]
Psychedelic therapy can helps patients face difficult emotions with curiosity, supporting deep healing and lasting change.
Sunstone Therapies Co-Founders Dr. Manish Agrawal and Kim Roddy spoke with Psychedelic Alpha’s Editor, Josh Hardman, about the challenges and insights they’ve gained after delivering hundred of psychedelic therapy sessions.
Psychedelic Medicine–History and Clinical Research January 30, 2025 Psychedelic Medicine: History and Clinical Research explores the resurgence of psychedelics in […]
Manish Agrawal, MD joins Living Medicine host, Dr. Sandra Newes to discuss the challenges and future of psychedelic-assisted therapy research.
Manish Agrawal, MD joins Power to the Patient host Brandon Li to discuss the transformative role of psychedelics in cancer care and mental health.